Josef Parvizi Sells 25,000 Shares of CeriBell (NASDAQ:CBLL) Stock

CeriBell, Inc. (NASDAQ:CBLL) Director Josef Parvizi sold 25,000 shares of CeriBell stock in a transaction that occurred on Thursday, January 15th. The stock was sold at an average price of $22.94, for a total transaction of $573,500.00. Following the sale, the director owned 747,652 shares in the company, valued at approximately $17,151,136.88. This represents a 3.24% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Josef Parvizi also recently made the following trade(s):

• On Monday, December 15th, Josef Parvizi sold 25,000 shares of CeriBell stock. The shares were sold at an average price of $21.49, for a total transaction of $537,250.00.
• On Monday, December 8th, Josef Parvizi sold 25,000 shares of CeriBell stock. The shares were sold at an average price of $20.26, for a total transaction of $506,500.00.

CeriBell Trading Down 2.2%

Shares of CeriBell stock traded down $0.49 during trading on Tuesday, hitting $21.45. The company’s stock had a trading volume of 218,895 shares, compared to its average volume of 395,791. The stock has a market cap of $795.80 million, a price-to-earnings ratio of -14.21 and a beta of 1.02. CeriBell, Inc. has a 52 week low of $10.01 and a 52 week high of $26.04. The stock has a 50-day moving average price of $19.35 and a two-hundred day moving average price of $15.21. The company has a debt-to-equity ratio of 0.12, a current ratio of 12.65 and a quick ratio of 12.25.

CeriBell (NASDAQ:CBLL) last issued its earnings results on Tuesday, November 4th. The company reported ($0.37) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.43) by $0.06. CeriBell had a negative net margin of 63.35% and a negative return on equity of 29.63%. The business had revenue of $22.59 million for the quarter, compared to analyst estimates of $21.78 million. Equities research analysts anticipate that CeriBell, Inc. will post -2.46 EPS for the current fiscal year.

Analyst Ratings Changes

A number of equities research analysts recently issued reports on the company. Cowen restated a “buy” rating on shares of CeriBell in a research note on Tuesday, December 9th. JPMorgan Chase & Co. reduced their target price on shares of CeriBell from $21.00 to $17.00 and set an “overweight” rating for the company in a research note on Wednesday, November 5th. TD Cowen dropped their price target on shares of CeriBell from $36.00 to $20.00 and set a “buy” rating on the stock in a research note on Wednesday, November 5th. Canaccord Genuity Group lifted their price objective on shares of CeriBell from $29.00 to $30.00 and gave the company a “buy” rating in a research note on Wednesday, December 17th. Finally, BTIG Research restated a “buy” rating and set a $30.00 target price on shares of CeriBell in a research report on Monday, December 15th. One research analyst has rated the stock with a Strong Buy rating, six have given a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat, CeriBell has an average rating of “Moderate Buy” and a consensus price target of $24.67.

Hedge Funds Weigh In On CeriBell

Hedge funds have recently modified their holdings of the company. CenterBook Partners LP increased its position in shares of CeriBell by 448.0% during the third quarter. CenterBook Partners LP now owns 476,554 shares of the company’s stock valued at $5,476,000 after buying an additional 389,584 shares during the period. JPMorgan Chase & Co. grew its holdings in shares of CeriBell by 6,424.8% during the 2nd quarter. JPMorgan Chase & Co. now owns 380,003 shares of the company’s stock worth $7,117,000 after acquiring an additional 374,179 shares during the period. Peregrine Capital Management LLC bought a new position in shares of CeriBell in the 2nd quarter worth approximately $6,399,000. TimesSquare Capital Management LLC lifted its stake in shares of CeriBell by 48.5% in the 2nd quarter. TimesSquare Capital Management LLC now owns 796,945 shares of the company’s stock valued at $14,927,000 after purchasing an additional 260,116 shares during the period. Finally, Millennium Management LLC boosted its position in shares of CeriBell by 41.8% during the third quarter. Millennium Management LLC now owns 666,448 shares of the company’s stock valued at $7,657,000 after purchasing an additional 196,299 shares in the last quarter.

CeriBell Company Profile

CeriBell Corp (NASDAQ: CBLL) is a healthcare technology company specializing in the design, manufacture and sale of automated newborn hearing screening devices. The company offers a suite of medical diagnostic tools based on otoacoustic emissions (OAE) and auditory brainstem response (ABR) technologies, enabling early detection of auditory impairments in infants. CeriBell’s solutions are used in hospitals, birthing centers and audiology clinics to support universal newborn hearing screening programs aimed at improving language development outcomes through prompt intervention.

The company’s product portfolio includes handheld and desktop screening units, proprietary software for data management, and accessories designed to streamline testing workflows.